HDAC4 and neoplasm: In a “synthetic lethality” scenario (Huang et al., 2020), the combination of blocking HDAC4 and using monoclonal antibodies against VEGF, such as bevacizumab, may be promising in the overwhelming landscape of tumor resistance, and some encouraging results have already been obtained (Zhang et al., 2017).